ADC Therapeutics SA
ADCT· NYSE
Released Aug 13, 2026, before the open
10-Q filed Aug 13, 2026, 44 days after period end · 0001628280-26-056711
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $18.63M | $18.09M | $17.03M | $19.20M |
| Net Income | -$16.57M | -$56.65M | -$36.54M | -$48.92M |
| EPS Diluted |
ADC Therapeutics SA · CIK 1771910 · Engraved from SEC EDGAR
| -$0.11 |
| -$0.50 |
| -$0.38 |
| -$0.60 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.